A Multiple-Dose Study of BLU-5937 in Chronic Pruritus Associated With Atopic Dermatitis

Inclusion Criteria:

• Willing to participate and is capable of giving informed consent
• Clinically confirmed diagnosis of active AD with at least a 6-month history of AD
• Chronic pruritus related to AD for at least 3 months
• Moderate to severe itch associated with mild to moderate AD
• Female of childbearing potential must agree to use a highly effective contraceptivemethod during the study and until at least 4 weeks after the last study drugadministration

Exclusion Criteria:

• History of skin disease or presence of skin condition that would interfere with thestudy assessments
• Clearly defined etiology for pruritus other than AD, including but not limited to:urticaria, psoriasis, or other non-atopic dermatologic conditions, hepatic or renaldisease, psychogenic pruritus, drug reaction, uncontrolled hyperthyroidism, andinfection
• Presence of any acute skin condition other than AD which may risk inducing a pruritusflare/worsening during the course of the study, including but not limited to:impetigo, active herpes simplex infection, or allergic contact dermatitis
• Subject is >65 years of age and has developed pruritus at age of ≥50 years
• History of cancer or lymphoproliferative disease within 5 years with the exception ofsuccessfully treated nonmetastatic cutaneous squamous cell or basal cell carcinomaand/or localized carcinoma in situ of the cervix
• Known history of, or active, parasitic infection, including skin parasites such asscabies within 12 months prior to Screening
• Known history of chronic infectious disease (e.g. hepatitis B, hepatitis C, or humanimmunodeficiency virus [HIV])
• Known history of clinically significant drug or alcohol abuse in the last year
• Previous participation in a BLU-5937 trial